Treatment of hepatitis C with new fixed dose combinations.

about

Need to Face Liver Cirrhosis after HCV Cure with Antivirals.NS5B polymerase inhibitors in phase II clinical trials for HCV infection.Current and future challenges in HCV: insights from an Italian experts panel.Is Ribavirin Teratogenic in Humans? No Evidence So Far.

P2860

Q41997594-DD2890EB-58D3-43A5-8228-DA1797FA9260 Q47260158-8E5FCA36-71F9-4AB7-99E0-EE324E8E976B Q47591971-5D32CB3F-8547-4E9C-95B6-7100F3E70FC5 Q50074863-67D7833B-88BD-4CD2-91EF-D917B32C2026

P2860

Treatment of hepatitis C with new fixed dose combinations.

Item

http://www.wikidata.org/entity/Q40148071

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment of hepatitis C with new fixed dose combinations.

@en

type

Item

label

Treatment of hepatitis C with new fixed dose combinations.

@en

prefLabel

Treatment of hepatitis C with new fixed dose combinations.

@en

P1476

Treatment of hepatitis C with new fixed dose combinations.

@en

P2093

Ana Arias

http://www.w3.org/2001/XMLSchema#string

Carmen de Mendoza

http://www.w3.org/2001/XMLSchema#string

José M Peña

http://www.w3.org/2001/XMLSchema#string

José V Fernandez-Montero

http://www.w3.org/2001/XMLSchema#string

Laura Benitez-Gutierrez

http://www.w3.org/2001/XMLSchema#string

Pablo Barreiro

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis C.

Hepatitis C virus infection.

Impact of Hepatitis C Treatment as Prevention for People Who Inject Drugs is sensitive to contact network structure.

Future of therapy for Hepatitis C in India: A Matter of Accessibility and Affordability?

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection

Rate, delay and predictors of hepatitis C treatment in British Columbia

Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV

Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection.

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.

P304

1235-1242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1346609

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vicente Soriano

P577

2017-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28644739

http://www.w3.org/2001/XMLSchema#string

Treatment of hepatitis C with new fixed dose combinations.

about

P2860

P2860

Treatment of hepatitis C with new fixed dose combinations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698